Telix Pharmaceuticals Ltd (ASX:TLX) ticked two important boxes this week: it met full-year revenue guidance and notched a fresh regulatory milestone in China. Yet the market response has been unforgiving.
The radiopharmaceuticals group fell more than 7% on Tuesday to $10.62, extending a bruising six-month decline that has now erased more than half its market value. The move came despite confirmation that Telix delivered US$804 million in FY25 revenue and despite China’s drug regulator accepting a new drug application for its prostate cancer imaging agent, Illuccix.
It was a solid update, but the share price reaction suggests investors are still grappling with bigger questions around timing, risk and what comes next.
Guidance delivered, growth intact
Telix’s performance update confirmed it hit the upper end of expectations in FY25, with unaudited group revenue of about US$804 million, in line with upgraded guidance of US$800–820 million.
Fourth-quarter revenue rose 46% year-on-year to roughly US$208 million, driven largely by ongoing demand for Illuccix and the early impact of Gozellix following reimbursement approval in the US. Management highlighted sequential growth in its Precision Medicine business and pointed to strong uptake across key accounts.
From an operational standpoint, this was a clean delivery. Telix has repeatedly shown it can commercialise products and scale revenue — a rare trait among ASX biotechs.
China opens a new door for Illuccix
Alongside the performance update, Telix announced that China’s National Medical Products Administration has accepted a new drug application for Illuccix, supported by positive Phase 3 data from a pivotal local study.
The trial reported a 94.8% positive predictive value in detecting recurrent prostate cancer and showed that more than two-thirds of patients experienced a change in treatment plan following Illuccix imaging — a meaningful clinical outcome.
China represents a strategically important market for Telix, both in terms of prostate cancer incidence and the rapid expansion of PET/CT infrastructure. Acceptance of the filing marks the company’s first product submission in China and lays the groundwork for longer-term geographic expansion.
Why the market is still cautious
Despite the positive news flow, Telix’s share price tells a story of restraint rather than enthusiasm.
Part of that reflects the stock’s history. Telix was a standout ASX healthcare performer through 2023 and early 2024, driven by real commercial success rather than speculative clinical promise. That success also pushed expectations higher — and left little tolerance for delays, regulatory friction or execution risk elsewhere in the portfolio.
Investors remain conscious of the company’s broader pipeline, particularly imaging and therapeutic programs that have faced regulatory setbacks in the US. While management has flagged constructive engagement with regulators and progress towards resubmissions, the timing and certainty of those pathways still matter to a market that has grown less patient.
Macro pressure on healthcare and growth stocks
The broader backdrop hasn’t helped. Healthcare stocks were among the weaker performers on the ASX on Wednesday, down more than 1% in a session where eight of the 11 sectors trended lower. Information technology and financials led declines, underscoring a broader risk-off tone.
Globally, healthcare and biotech remain out of favour as investors continue to prioritise near-term earnings certainty and balance-sheet strength, with interest-rate expectations still being pushed out. Even profitable biotechs are being judged more harshly in this environment.
A reset, not a rejection
Telix is now trading less like a momentum biotech and more like a mature healthcare company under scrutiny. The stock is down about 11% over the past month and nearly 60% over six months — a sharp reset that reflects both sector-wide caution and company-specific fatigue.
China’s Illuccix milestone and FY25 delivery reinforce Telix’s commercial credibility. But in the current market, investors appear to be waiting for clearer visibility on the next phase of growth — and a more supportive macro backdrop — before re-engaging.
For Telix, the task ahead is no longer about proving the business works. It’s about rebuilding confidence that the growth story still has meaningful distance left to run.